Jim Cramer highlights Butterfly Network’s AI-driven ultrasound tech as a speculative buy near $8 despite no profitability.
Jim Cramer labeled Butterfly Network (NYSE:BFLY) a compelling speculative investment at $8, citing its AI-powered handheld ultrasound devices. The stock, which enables whole-body imaging via smartphones, remains unprofitable but offers growth potential in a competitive medical device market.
Butterfly Network operates in a crowded sector, with even established players like GE Healthcare struggling to sustain gains. Cramer acknowledged the company’s promise but cautioned about the challenges of the medical device industry, calling it “too hard” for his preference.
The stock was discussed during a February 6 *Mad Money* episode, where Cramer reiterated his long-standing interest in BFLY as a high-risk, high-reward play.